DualityBio Included in Hong Kong Exchange TECH-100 Index and FTSE Global Equity Index Series Small Cap Constituents

DualityBio's Innovative ADC DB-1324 Receives FDA IND Clearance, Set to Initiate Clinical Trial in the United States

Duality Biologics Orally Presents Phase 1 Healthy Volunteer Data for First-in-Class BDCA2-Targeted ADC DB-2304 at Autumn Immunology Conference 2025

First Patient Dosed in Phase I/IIa Study of DualityBio’s BDCA2-Targeting ADC DB-2304 for Systemic Lupus Erythematosus

Fast Track Designation Granted for AVZO-1418/DB-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC

DualityBio DB-1324 HREC approval obtained and received TGA acknowledgment of the eCTN